دورية أكاديمية
أعرض في EDS

Clinical Impacts of Pseudomonas aeruginosa Isolation in Patients with Bronchiectasis: Findings from KMBARC Registry.

التفاصيل البيبلوغرافية
العنوان: Clinical Impacts of Pseudomonas aeruginosa Isolation in Patients with Bronchiectasis: Findings from KMBARC Registry.
المؤلفون: Song J; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul 05368, Republic of Korea., Sin S; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Center, Seoul 04564, Republic of Korea., Kang HR; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul 05368, Republic of Korea., Oh YM; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea., Jeong I; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Center, Seoul 04564, Republic of Korea.
مؤلفون مشاركون: KMBARC
المصدر: Journal of clinical medicine [J Clin Med] 2024 Aug 24; Vol. 13 (17). Date of Electronic Publication: 2024 Aug 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2012]-
مستخلص: Background: Pseudomonas aeruginosa isolation in bronchiectasis is associated with a poor prognosis, including increased hospital admissions, exacerbation, and mortality. In this study, we aimed to evaluate the clinical characteristics and outcomes of P. aeruginosa isolation from patients with bronchiectasis in South Korea. Methods: This multicenter prospective cohort study analyzed 936 patients with bronchiectasis. We examined the prevalence of P. aeruginosa isolates and other microbiological characteristics. Additionally, the clinical characteristics related to disease severity and 1-year prognosis were compared between patients with and without P. aeruginosa isolation. Propensity score matching was used to mitigate confounding biases. Results: Of the 936 patients with bronchiectasis, P. aeruginosa was isolated from 89. A total of 445 matched patients-356 patients without (non- Pseudomonas group) and 89 with ( Pseudomonas group) P. aeruginosa isolation-were analyzed. The Pseudomonas group showed poorer lung function, greater involvement of radiographic bronchiectasis, and a higher proportion of cystic bronchiectasis than the non- Pseudomonas group. After one year, more patients in the Pseudomonas group were admitted for bronchiectasis than in the non- Pseudomonas group. Moreover, the Bronchiectasis Health Questionnaire scores were significantly lower in the Pseudomonas group than in the non- Pseudomonas group. Conclusions: The isolation of P. aeruginosa was independently associated with increased disease severity and poor clinical outcomes in Korean patients with bronchiectasis.
References: Lancet Respir Med. 2023 Jul;11(7):637-649. (PMID: 37105206)
Pediatr Pulmonol. 2002 Aug;34(2):91-100. (PMID: 12112774)
Thorax. 1997 Mar;52(3):260-4. (PMID: 9093343)
ERJ Open Res. 2016 Jan 20;2(1):. (PMID: 27730179)
Respir Res. 2021 Apr 28;22(1):132. (PMID: 33910573)
J Bras Pneumol. 2022 Jul 08;48(3):e20220075. (PMID: 35830054)
Eur J Clin Microbiol Infect Dis. 2019 Dec;38(12):2299-2304. (PMID: 31471703)
Ann Am Thorac Soc. 2014 May;11(4):496-503. (PMID: 24592925)
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1277-84. (PMID: 11029331)
Expert Rev Respir Med. 2021 May;15(5):649-662. (PMID: 33736539)
Am J Respir Crit Care Med. 2013 Sep 15;188(6):647-56. (PMID: 23898922)
Clin Microbiol Infect. 2021 Mar;27(3):428-434. (PMID: 32311472)
QJM. 2012 Mar;105(3):235-40. (PMID: 22016379)
Eur J Intern Med. 2003 Dec;14(8):488-492. (PMID: 14962701)
Chest. 1998 Dec;114(6):1594-8. (PMID: 9872194)
Eur Respir J. 2006 Nov;28(5):974-9. (PMID: 16899482)
Respir Med. 2014 Feb;108(2):287-96. (PMID: 24445062)
Eur Respir J. 2017 May 11;49(5):. (PMID: 28495688)
Respir Med. 2007 Aug;101(8):1633-8. (PMID: 17467966)
Chest. 2007 Nov;132(5):1565-72. (PMID: 17998359)
Eur Respir J. 2014 May;43(5):1357-67. (PMID: 24232697)
J Thorac Dis. 2015 Apr;7(4):625-36. (PMID: 25973228)
BMJ Open. 2020 Jan 19;10(1):e034090. (PMID: 31959610)
Eur Respir J. 1997 Aug;10(8):1754-60. (PMID: 9272915)
Eur Respir J. 2017 Jun 8;49(6):. (PMID: 28596426)
Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85. (PMID: 24328736)
Chest. 2000 Feb;117(2):420-6. (PMID: 10669685)
Int J Chron Obstruct Pulmon Dis. 2018 Jan 09;13:237-246. (PMID: 29386892)
Ann Am Thorac Soc. 2015 Nov;12(11):1602-11. (PMID: 26356317)
Tuberc Respir Dis (Seoul). 2020 Jul;83(3):228-233. (PMID: 32578411)
Respirology. 2021 Jun;26(6):619-621. (PMID: 33876470)
PLoS One. 2014 Nov 18;9(11):e113373. (PMID: 25405614)
Respir Med. 2015 Jun;109(6):716-26. (PMID: 25200914)
J Glob Infect Dis. 2015 Jan-Mar;7(1):18-22. (PMID: 25722615)
Clin Microbiol Infect. 2020 Mar;26(3):313-318. (PMID: 31306794)
فهرسة مساهمة: Keywords: Pseudomonas aeruginosa; bronchiectasis; prognosis
تواريخ الأحداث: Date Created: 20240914 Latest Revision: 20240916
رمز التحديث: 20240916
مُعرف محوري في PubMed: PMC11396479
DOI: 10.3390/jcm13175011
PMID: 39274224
قاعدة البيانات: MEDLINE
الوصف
تدمد:2077-0383
DOI:10.3390/jcm13175011